Childhood-onset vs adult-onset patients with SLE: baseline demographics, concomitant medications, and clinical manifestations leading to treatment with belimumab.
| Characteristics | Baseline | |
|---|---|---|
| Childhood-onset SLE, n = 39 | Adult-onset SLE, n = 156 | |
| Women (%) | 90 | 92.3 |
| Mean age at diagnosis, yrs | 14 ± 4 | 33 ± 12 |
| Disease duration at initiation of belimumab, yrs | 12 ± 8 | 11 ± 7 |
| Age at initiation of belimumab, yrs | 27 ± 7* | 45 ± 11* |
| Race, % | ||
| White | 46 | 65 |
| Black | 48 | 25 |
| Asian | 6 | 6 |
| Other | 0 | 4 |
| Ethnicity, % | ||
| Hispanic/Latino | 12 | 4 |
| Clinical manifestations, % | ||
| Arthritis | 46 | 70 |
| Rash | 36 | 45 |
| Constitutional | 13 | 27 |
| Inability to taper steroids | 82 | 28 |
| Renal | 15 | 11 |
| Neuropsychiatric SLE | 0 | 10 |
| Laboratory manifestations, % | ||
| Hematologic | 5 | 12 |
| Hypocomplementemia | 59 | 52 |
| Elevated anti-dsDNA antibodies | 84 | 29 |
| Concomitant medications, % | ||
| Antimalarials | 92 | 68 |
| Prednisone | 82* | 72 |
| Mean dose prednisone equivalent | 17 mg/day* | 11 mg/day |
| Immunosuppressive agents | 72 | 53 |
| Mycophenolate | 49 | 33 |
| Azathioprine | 23 | 20 |
| Methotrexate | 0 | 14 |
| Angiotensin-converting enzyme inhibitor | 8 | 4 |
| No SLE medications | 0 | 4 |
↵* p < 0.05. SLE: systemic lupus erythematosus.